Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger. The resulting company will continue under the Alumis name at the ...

Wilmington, Delaware--(Newsfile Corp. - February 12, 2025) - Rigrodsky Law, P.A. is investigating Acelyrin, Inc. ("Acelyrin") (NASDAQ: SLRN) regarding possible ...

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement in an all-stock transaction, allowing Alumis to leverage increased financial flexibility and an expanded late-stage ...

Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former lead candidate that began with the axing of development in two diseases in August.

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on ACELYRIN, INC. (SLRN – Research Report). The company’s shares closed yesterday at $1.90. Leverage the ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ACELYRIN, INC. (NASDAQ: SLRN) to Alumis Inc. for 0.4274 shares of Alumis common stock ...

Alumis and Acelyrin have announced a definitive merger agreement, which will result in an all-stock transaction, creating a late-stage clinical biopharma company. The merged company will focus on ...

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement for an all-stock transaction, with stockholders of each company owning approximately 55% and 45% of the combined entity ...

Alumis (ALUM) shares plunged ~17% in the premarket on Friday after the immunology-focused biopharma agreed to merge with its California-based rival Acelyrin (NASDAQ:SLRN) in an all-stock transaction.

MILWAUKEE--(BUSINESS WIRE)--Ademi & Fruchter LLP is investigating ACELYRIN (Nasdaq: SLRN) for possible breaches of fiduciary duty and other violations of law in its transaction with Alumis.

AGOURA HILLS, CA – ACELYRIN, Inc. (SLRN), a biopharmaceutical company with a market capitalization of approximately $199 million, has terminated its License and Collaboration Agreement with ...

Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 million on February 6. Upon completion of the deal, which is expected to ...